InventisBio Co. Ltd. A (688382) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of InventisBio Co. Ltd. A stock ¥7.76, price ¥12.39, that is 37.4% below the price, quality 40 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
InventisBio Co. Ltd. A
688382 · SHGFar too expensive (fair value 37% below the price), weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.
How to read this chart
52‑month range ¥6.72 – ¥47.90 · fair‑value band ¥5.82 – ¥9.70 · the ¥12.39 price screens above the ¥7.76 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.
Every Wednesday you see whether InventisBio Co. Ltd. A is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
InventisBio Co., Limited, a clinical stage biotech company, focuses on areas of oncology, autoimmune diseases, and metabolic disorders to address unmet medical needs in China.
Show moreShow less
Its product pipeline for the oncology therapeutic area include Befoternitib (BPI-D0316), which is in Phase III clinical trial for the non-small cell lung cancer (NSCLS) indications; Garsorasib (D-1553), which is in phase II and III clinical trials to treat NSCLS and colorectal cancer; Taragarestrant (D-0502), which is in phase III and II to treat estrogen receptor positive/human epidermal growth factor receptor 2-breast cancer.
The company also develops D"2570, which is in phase III, II, and I clinical trials, as well as preclinical trials to treat autoimmune disease; and Darbinurad (D-0120), which is in phase II clinical trial to treat gout.
In addition, it is developing YF087 which is in preclinical trial to treat MSI-high solid tumors; YF550 which is in preclinical trial to treat chromosome instability solid tumors; and YF057 which is in preclinical trial to treat atopic dermatitis and asthma.
InventisBio Co., Limited was founded in 2013 and is based in Shanghai, China.
Stock analysis
InventisBio Co. Ltd. A (688382) currently trades at ¥12.39, while our estimate is ¥7.76, 37% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: ¥5.82 (bear) to ¥9.70 (bull), the price of ¥12.39 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak, negative or inconsistent.
InventisBio Co. Ltd. A reported revenue of 37.3M CNY in FY2025 versus 0 CNY in FY2021. Reported net income was −317M CNY in FY2025.
Key figures
Market cap 7.4B CNY (≈ $1.1B) Small · EPS (TTM) ¥−0.5900 · Return on equity −21.4% · Return on assets (EBIT) −22.9% (5-year average) · Operating margin −940% · Revenue (TTM) 71.4M CNY · Revenue growth (YoY) −1.8% · Free cash flow −162M CNY.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).
What moves the price
The share trades about 63% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −37%, 688382 screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Compare InventisBio Co. Ltd. A with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 847 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- EV/EBITDA by industry
- Dividend yield by industry
- PEG screener for stocks with fair value
- Undervalued stocks: Chinese Stocks
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs 688382 |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs 688382 |
| Samsung Biologics Co 207940 | 1,423,000 KRW | 1,552,100 KRW | +9% | vs 688382 |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs 688382 |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs 688382 |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs 688382 |
| BeOne Medicines AG 6160 | HK$249.40 | HK$152.92 | −39% | vs 688382 |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs 688382 |
| Celltrion, Inc 068270 | 214,500 KRW | 74,945 KRW | −65% | vs 688382 |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs 688382 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is InventisBio Co. Ltd. A (688382) overvalued or undervalued?
What is the fair value of 688382?
What is the quality score of 688382?
What is the price target for InventisBio Co. Ltd. A (688382)?
What is the InventisBio Co. Ltd. A stock forecast for 2026?
What is the revenue of InventisBio Co. Ltd. A (688382)?
What is the intrinsic value of InventisBio Co. Ltd. A (688382)?
Is InventisBio Co. Ltd. A stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 688382?
How much is InventisBio Co. Ltd. A worth?
What do the bullish and bearish scenarios say about 688382?
How solid is the balance sheet of InventisBio Co. Ltd. A (688382)?
How far is 688382 from its 52-week high?
Which stocks are comparable to InventisBio Co. Ltd. A?
Is InventisBio Co. Ltd. A stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of InventisBio Co. Ltd. A (688382)?
What should I pay attention to with InventisBio Co. Ltd. A right now?
Key figures of InventisBio Co. Ltd. A
How large is the market capitalisation of InventisBio Co. Ltd. A (688382)?
What are the earnings per share of InventisBio Co. Ltd. A (688382)?
What is the return on equity of InventisBio Co. Ltd. A (688382)?
What is the EBIT return on assets of InventisBio Co. Ltd. A (688382)?
What is the operating margin of InventisBio Co. Ltd. A (688382)?
How fast is revenue growing at InventisBio Co. Ltd. A (688382)?
How much free cash flow does InventisBio Co. Ltd. A (688382) generate?
Watch InventisBio Co. Ltd. A in the live analysis
One click puts InventisBio Co. Ltd. A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.